Atlas Venture Announces That Nessan Bermingham Re-Joins as Venture Partner

Feb. 6, 2018 11:55 UTC

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Atlas Venture, a leading early stage biotech venture capital firm, today announced that Nessan Bermingham, founding CEO of Atlas-backed Intellia Therapeutics (NASDAQ: NTLA), is re-joining the firm as a venture partner. Nessan will be involved with the formation and leadership of groundbreaking new biotechnology companies as part of the Atlas platform.

"I am thrilled to be working with Atlas again as we translate cutting-edge scientific advances into medicines for patients in need and build great companies," said Bermingham.

Bermingham co-founded Intellia Therapeutics with Atlas Venture in 2014, leading the company from its seed investment and incubation at Atlas through its IPO and the advancement of its gene editing platform toward clinical development. He first joined Atlas in 2002 and worked on multiple Atlas portfolio companies across various stages and therapeutic areas, including the formation of several seed companies, before co-founding Intellia.

“Nessan is a relentless entrepreneur and operator who has proven his ability to build breakthrough biotech companies from the ground up," said Jean François Formela, partner at Atlas Venture. “We are excited to welcome him back to Atlas and look forward to creating transformational new companies with him."

About Atlas Venture

Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, we have been building breakthrough biotech startups since 1993. We work side by side with exceptional scientists and entrepreneurs to translate high impact science into medicines for patients. Our seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value. For more information, please visit




Atlas Venture
Kristen Margeson, 857-201-2700
Director of Investor Relations and Marketing


Source: Atlas Venture

Back to news